%0 Journal Article
%K Adult
%K Aged
%K Bell Palsy/*epidemiology
%K COVID-19/*prevention & control
%K COVID-19 Vaccines/*administration & dosage
%K Encephalomyelitis/*epidemiology
%K Female
%K Guillain-Barre Syndrome/*epidemiology
%K Humans
%K Incidence
%K Male
%K Middle Aged
%K Myelitis, Transverse/*epidemiology
%K Routinely Collected Health Data
%K SARS-CoV-2/*immunology
%K Spain
%K United Kingdom
%K Vaccination/adverse effects
%B Bmj
%D 2022
%G eng
%M 35296468
%P e068373
%R 10.1136/bmj-2021-068373
%T Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis
%V 376
%2 PMC8924704 authors. XL, BR, DP-A, TD-S, EB, and VS conceived the study and contributed to the study design. XL, BR, ER, and AP conducted the statistical analyses. XL, BR, ER, VS, DP-A, EB, and TD-S interpreted the results and wrote the manuscript. All authors contributed to writing the manuscript, approved the final version, and had final responsibility for the decision to submit for publication. TD-S, EB, and DP-A are guarantors. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. Competing interests: All authors have completed the ICMJE disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare the following interests: DP-A receives funding from the UK National Institute for Health Research (NIHR) in the form of a senior research fellowship and from the Oxford NIHR Biomedical Research Centre. XL receives the Clarendon Fund and Brasenose College scholarship (University of Oxford) to support her DPhil study. DP-A’s research group has received research grants from the European Medicines Agency; the Innovative Medicines Initiative; and Amgen, Chiesi, and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, AstraZeneca, and UCB Biopharma.
%7 2022/03/18
%@ 0959-8138 (Print)
0959-8138